DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Still a Buy?

DBV Technologies S.A. (NASDAQ:DBVT) shares gapped up prior to trading on Wednesday . The stock had previously closed at $22.50, but opened at $24.79. DBV Technologies shares last traded at $23.9920, with a volume of 106,535 shares changing hands.

Wall Street Analyst Weigh In

DBVT has been the topic of a number of recent research reports. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday. Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a research note on Wednesday, December 17th. HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a research report on Thursday, December 18th. Guggenheim restated a “buy” rating and set a $51.00 target price (up previously from $35.00) on shares of DBV Technologies in a report on Wednesday, December 17th. Finally, Citizens Jmp lifted their price target on shares of DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a research note on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.38.

DBV Technologies Stock Up 3.6%

The stock has a market cap of $935.93 million, a P/E ratio of -4.51 and a beta of -0.98. The firm has a 50 day simple moving average of $18.83 and a 200-day simple moving average of $14.19.

Insider Buying and Selling

In other news, major shareholder Bpifrance Epic sold 2,076,990 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total value of $10,073,401.50. Following the transaction, the insider directly owned 8,595,472 shares of the company’s stock, valued at $41,688,039.20. This represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 3,369,627 shares of company stock worth $15,489,908 over the last three months. Insiders own 1.44% of the company’s stock.

Institutional Investors Weigh In On DBV Technologies

A number of institutional investors have recently made changes to their positions in DBVT. Vivo Capital LLC bought a new position in shares of DBV Technologies during the second quarter worth approximately $9,659,000. Adage Capital Partners GP L.L.C. acquired a new position in DBV Technologies in the 2nd quarter valued at $9,659,000. MPM Bioimpact LLC bought a new position in DBV Technologies during the 2nd quarter worth $9,649,000. Octagon Capital Advisors LP acquired a new stake in shares of DBV Technologies during the second quarter worth $9,315,000. Finally, UBS Group AG lifted its holdings in shares of DBV Technologies by 165,347.3% during the fourth quarter. UBS Group AG now owns 244,862 shares of the company’s stock worth $4,694,000 after buying an additional 244,714 shares in the last quarter. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.